Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Quest Diagnostics has entered into a definitive agreement to acquire laboratory-related clinical outreach service operations of Dignity Health, a hospital system based in California. Under the agreement, Quest will acquire operations through which Dignity Health provides outreach diagnostic information services to patients and physician offices in parts of California and Nevada.
Quidel Corp. has completed its acquisition of BioHelix Corp. According to terms of the deal, Quidel will pay BioHelix shareholders $10 million in cash, plus additional amounts in connection with an R&D earn-out based on the completion of a designated number of assays and a commercial earn-out dependent on product sales over a defined period.
Applied Spectral Imaging and BioDot have entered into an agreement under which both companies will engage in combined sales and marketing of a product that will directly link ASI’s GenASIs imaging and analysis instrument and BioDot’s CellWriter automated dispensing system for FISH and karyotyping.
Meridian Bioscience has received FDA clearance for its Mycoplasma pneumoniae molecular diagnostic test on the Illumigene platform. By amplifying the specific DNA for the detection of M. pneumoniae, the test provides a definitive result, thus helping to ensure that patients receive the appropriate antibiotic therapy in a timely manner.
Beckman Coulter Life Sciences’ VersaComp antibody capture bead kits are designed to set compensation for multicolor flow cytometry experiments by allowing researchers to use the same reagents as they do in their experiments.
BioMérieux’s Labguard is a real-time wireless, automated, temperature-monitoring solution for hospitals, laboratories, blood banks, and pharmacies. The solution features real-time, 24/7 Web-based monitoring with alarm display and notifications via SMS, e-mail, and fax. The solution has sensor probes for different applications, including temperature, humidity, pressure, and other physical parameters.
DiaSorin’s Liaison IGF-1 assay is a solution for full automation of growth factor testing on a random-access analyzer, for accurately monitoring growth dysfunctions. The company offers an extensive menu of reliable, fully automated chemiluminescent assays suitable for endocrinology clinics, reference laboratories, hospitals, and physician office laboratories. Patients benefit from rapid and accurate results, and laboratories benefit from fast turnaround time and ease of use with the Liaison assay product portfolio.
Hoefer’s new Web site was designed to create a more positive experience with improved navigation, more product information, an enhanced storefront, and more technical literature available to download. A dealer portal section has also been added to improve the communication of support materials with channel partners. The site was designed to resize to device-display resolution, enabling a better experience for desktops, tablets, and mobile devices.
SeraCare Life Sciences offers three new Accuvert seroconversion panels and one new Accuset performance panel. The new Accuvert seroconversion panels are HCV seroconversion panel PHV924, providing undiluted plasma samples from a single male donor of genotype 2b, drawn over an 88-day period in 2008; HCV seroconversion panel PHV925, providing undiluted plasma samples from a single male donor of genotype 1a, drawn over a 27-day period in 2008; and HCV seroconversion panel PHV926, providing undiluted plasma samples from a single male donor of genotype 3a, drawn over a 14-day period in 2009.
Last year, Semrock opened a high-capacity manufacturing facility for its optical filter products. Having entered full-scale production, the company now supports its OEM customers by producing spectrally complex, hard-coated sputtered optical filters with high-volume pricing. Semrock’s products are available to the emerging diagnostic and point-of-care health care and display and sensing markets, where high-performance, miniaturized optical filters are an enabling technology.
